Quick Answer
Amylyx Pharmaceuticals, Inc. reported R&D Expense of $90.40 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $90.40M | -13.1% |
| 2024 | $104.08M | -18.8% |
| 2023 | $128.19M | +37.2% |
| 2022 | $93.45M | +112.2% |
| 2021 | $44.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $19.86M | -6.5% | -27.0% |
| June 30, 2025 | $27.22M | +16.6% | +23.0% |
| March 31, 2025 | $22.12M | -39.6% | +4.2% |
| September 30, 2024 | $21.24M | -29.3% | -9.0% |
| June 30, 2024 | $23.35M | -19.6% | -36.2% |
| March 31, 2024 | $36.61M | +51.3% | +21.9% |
| September 30, 2023 | $30.04M | +20.6% | +3.4% |
| June 30, 2023 | $29.04M | +19.7% | +20.1% |
- Amylyx Pharmaceuticals, Inc. showed a decrease of -13.1% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s r&d expense has grown by 105.3% (from $44.04 million to $90.40 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: